Group 1 - The core point of the article is that China Health Technology Group (01069) has completed a share placement agreement, with 17 million shares issued at a price of HKD 0.28 per share, representing approximately 16.52% of the company's enlarged issued share capital after the placement [1] - On August 15, shareholders transferred shares from Changli Securities to China Northern Securities Group, with a market value of HKD 2.8426 million, accounting for 5.64% of the total [1] - The placement agreement's conditions have been fully met, and the placement was completed on August 1, 2025 [1]

Group 1 - The core point of the article is that China Health Technology (01069) has completed a placement agreement, issuing 17 million shares at a price of HKD 0.28 per share, which represents approximately 16.52% of the company's enlarged issued share capital after the placement [1] Group 2 - As of August 1, the shareholders of China Health Technology deposited shares worth HKD 6.46 million into Changli Securities, accounting for 16.52% of the total [1] - The placement was completed on August 1, 2025, with all conditions of the placement agreement met [1]

Group 1 - The core point of the article is that China Health Technology (01069) has completed a placement agreement, with 17 million shares issued at a price of HKD 0.28 per share, representing approximately 16.52% of the company's enlarged issued share capital after the placement [1] Group 2 - As of August 1, shareholders deposited stocks worth HKD 6.46 million into Changli Securities, accounting for 16.52% of the total [1] - The placement was completed on August 1, 2025, with all conditions of the placement agreement met [1]

Core Viewpoint - China Health Technology Group (01069) has completed the placement agreement, with the placement of 17 million shares at a price of HKD 0.28 per share, representing approximately 16.52% of the company's enlarged issued share capital post-placement [1] Summary by Relevant Sections - **Placement Completion**: The placement has been finalized as of August 1, 2025, with all conditions of the placement agreement met [1] - **Share Details**: A total of 17 million shares were issued to no less than six subscribers under the terms of the placement agreement [1] - **Capital Impact**: The issuance of shares will increase the company's issued share capital by approximately 16.52% following the completion of the placement [1]

Group 1 - The core point of the article is that China Health Technology Group (01069.HK) has completed a placement agreement, issuing a total of 17 million shares at a price of HKD 0.28 per share, which represents approximately 16.52% of the company's enlarged issued share capital post-placement [1] - The net proceeds from the placement amount to approximately HKD 4.63 million [1] - The company plans to use the net proceeds for various purposes, including approximately HKD 1.45 million for leasing expenses, approximately HKD 0.58 million for employee costs, and approximately HKD 2.6 million for professional fees [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) 01069 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股份代號：1069） 完成根據一般授權配售新股份 配售代理 昌利證券有限公司 茲提述本公司日期為二零二五年七月二十二日內容有關根據一般授權配售新股份 之公告（「該公告」）。除另有界定者外，本公告所用詞彙與該公告所界定者具有相 同涵義。 完成根據一般授權配售新股份 董事會欣然宣佈，配售協議的所有條件已獲達成，而配售事項已於二零二五年八 月一日完成。合共17,000,000股配售股份已根據配售協議之條款及條件按配售價每 股配售股份0.28港元配發及發行予不少於六名承配人，相當於緊隨完成後經配發 及發行配售股份擴大之本公司已發行股本約16.52%。據董事經作出一切合理查詢 1 後所深知、盡悉及確信，(i) 各承配人為獨立第三方；及(ii) 概無承配人於緊隨配售 事項完成後成為主要股東（ ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國健康科技集團控股有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 FF301 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01069 | 說明 | 普通股 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | | 已發行股份總數 | | | 上月底結存 | | | 859,242,204 | | | 0 | | 859,242,204 | | 增加 / 減少 (-) | | | -773,317,984 | | | 0 | | | | 本月底結存 | | | 85,924,220 | | | 0 | | 85,924 ...

Group 1 - Nanshan Aluminum International (02610.HK) expects a mid-term net profit of approximately $225 million to $265 million for the six months ending June 30, 2025, compared to a net profit of about $159 million for the same period ending June 30, 2024 [1] - The increase in net profit is primarily attributed to an improvement in gross margin, driven by higher alumina prices and relatively stable unit production costs [1] - The average selling price of the company's products for the first half of 2025 is expected to be around $530 per ton, up from approximately $387 per ton in the first half of 2024, but lower than $561 per ton in the second half of 2024 [1] Group 2 - TCL Electronics (01070.HK) anticipates a year-on-year adjusted net profit growth of approximately 45% to 65% for the first half of 2025 [2] - Renrui Talent (06919.HK) expects a mid-term profit attributable to equity holders to increase by 66.7% to 94.1% [2] - China Rare Earth Holdings (03788.HK) reports an increase in total gold resources to 5.07 million ounces [2]

Core Viewpoint - The Hong Kong Stock Exchange has imposed disciplinary actions against two former directors of China Health Technology Group Holdings Limited for failing to fulfill their duties and not cooperating with the investigation regarding company lending activities and the sale of subsidiaries [1][2]. Group 1: Disciplinary Actions - The Hong Kong Stock Exchange declared that former executive director Wang Yue and former independent non-executive director Tian Guangmei are unsuitable to hold any director or senior management positions in the company or its subsidiaries [1]. - The disciplinary actions stem from their involvement in company lending activities from 2015 to 2019 and the sale of subsidiaries in 2018, where they did not fulfill their director responsibilities [1][2]. Group 2: Investigation Findings - Evidence revealed that Wang, responsible for the company's lending operations, approved loans totaling HKD 138.3 million without adequate due diligence, risk analysis, or credit assessment [2]. - It was found that some lenders were Wang's family members, and there was no evidence that he disclosed this information [2]. - The company recorded an approximately 86% impairment on receivables related to these loans in its 2019 annual results [2]. Group 3: Sale of Subsidiaries - In 2018, Wang and Tian facilitated the postponement of a payment of RMB 93 million from the buyer without guarantees or interest, which ultimately led to a full impairment of this amount in the company's 2019 results [2]. - There was no evidence that either Wang or Tian conducted any due diligence or credit assessment on the buyer prior to the sale [2]. - After resigning from their director positions, both individuals failed to respond to the Stock Exchange's investigation and reminder letters [2].